Searched for: in-biosketch:true
person:katzm06
REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer
Boggi, Ugo; Kauffmann, Emanuele; Napoli, Niccolò; Barreto, S George; Besselink, Marc G; Fusai, Giuseppe K; Hackert, Thilo; Abu Hilal, Mohammad; Marchegiani, Giovanni; Salvia, Roberto; Shrikhande, Shailesh V; Truty, Mark; Werner, Jens; Wolfgang, Christopher L; Bannone, Elisa; Capretti, Giovanni; Cattelani, Alice; Coppola, Alessandro; Cucchetti, Alessandro; De Sio, Davide; Di Dato, Armando; Di Meo, Giovanna; Fiorillo, Claudio; Gianfaldoni, Cesare; Ginesini, Michael; Hidalgo Salinas, Camila; Lai, Quirino; Miccoli, Mario; Montorsi, Roberto; Pagnanelli, Michele; Poli, Andrea; Ricci, Claudio; Sucameli, Francesco; Tamburrino, Domenico; Viti, Virginia; Addeo, Pietro F; Alfieri, Sergio; Bachellier, Philippe; Baiocchi, Gian Luca; Balzano, Gianpaolo; Barbarello, Linda; Brolese, Alberto; Busquets, Juli; Butturini, Giovanni; Caniglia, Fabio; Caputo, Damiano; Casadei, Riccardo; Chunhua, Xi; Colangelo, Ettore; Coratti, Andrea; Costa, Francesca; Crafa, Francesco; Dalla Valle, Raffaele; De Carlis, Luciano; de Wilde, Roeland F; Del Chiaro, Marco; Di Benedetto, Fabrizio; Di Sebastiano, Pierluigi; Dokmak, Safi; Hogg, Melissa; Egorov, Vyacheslav I; Ercolani, Giorgio; Ettorre, Giuseppe Maria; Falconi, Massimo; Ferrari, Giovanni; Ferrero, Alessandro; Filauro, Marco; Giardino, Alessandro; Grazi, Gian Luca; Gruttadauria, Salvatore; Izbicki, Jakob R; Jovine, Elio; Katz, Matthew; Keck, Tobias; Khatkov, Igor; Kiguchi, Gozo; Kooby, David; Lang, Hauke; Lombardo, Carlo; Malleo, Giuseppe; Massani, Marco; Mazzaferro, Vincenzo; Memeo, Riccardo; Miao, Yi; Mishima, Kohei; Molino, Carlo; Nagakawa, Yuichi; Nakamura, Masafumi; Nardo, Bruno; Panaro, Fabrizio; Pasquali, Claudio; Perrone, Vittorio; Rangelova, Elena; Liu, Rong; Romagnoli, Renato; Romito, Raffaele; Rosso, Edoardo; Schulick, Richard; Siriwardena, Ajith; Spampinato, Marcello Giuseppe; Strobel, Oliver; Testini, Mario; Troisi, Roberto Ivan; Uzunoglo, Faik G; Valente, Roberto; Veneroni, Luigi; Zerbi, Alessandro; Vicente, Emilio; Vistoli, Fabio; Vivarelli, Marco; Wakabayashi, Go; Zanus, Giacomo; Zureikat, Amer; Zyromski, Nicholas J; Coppola, Roberto; D'Andrea, Vito; Davide, José; Dervenis, Christos; Frigerio, Isabella; Konlon, Kevin C; Michelassi, Fabrizio; Montorsi, Marco; Nealon, William; Portolani, Nazario; Sousa Silva, DonzÃlia; Bozzi, Giuseppe; Ferrari, Viviana; Trivella, Maria G; Cameron, John; Clavien, Pierre-Alain; Asbun, Horacio J; ,
OBJECTIVE:The REDISCOVER consensus conference aimed at developing and validating guidelines on the perioperative care of patients with borderline-resectable (BR-) and locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC). BACKGROUND:Coupled with improvements in chemotherapy and radiation, the contemporary approach to pancreatic surgery supports the resection of BR-PDAC and, to a lesser extent, LA-PDAC. Guidelines outlining the selection and perioperative care for these patients are lacking. METHODS:The Scottish Intercollegiate Guidelines Network (SIGN) methodology was used to develop the REDISCOVER guidelines and create recommendations. The Delphi approach was used to reach a consensus (agreement ≥80%) among experts. Recommendations were approved after a debate and vote among international experts in pancreatic surgery and pancreatic cancer management. A Validation Committee used the AGREE II-GRS tool to assess the methodological quality of the guidelines. Moreover, an independent multidisciplinary advisory group revised the statements to ensure adherence to nonsurgical guidelines. RESULTS:Overall, 34 recommendations were created targeting centralization, training, staging, patient selection for surgery, possibility of surgery in uncommon scenarios, timing of surgery, avoidance of vascular reconstruction, details of vascular resection/reconstruction, arterial divestment, frozen section histology of perivascular tissue, extent of lymphadenectomy, anticoagulation prophylaxis, and role of minimally invasive surgery. The level of evidence was however low for 29 of 34 clinical questions. Participants agreed that the most conducive means to promptly advance our understanding in this field is to establish an international registry addressing this patient population ( https://rediscover.unipi.it/ ). CONCLUSIONS:The REDISCOVER guidelines provide clinical recommendations pertaining to pancreatectomy with vascular resection for patients with BR-PDAC and LA-PDAC, and serve as the basis of a new international registry for this patient population.
PMCID:11161250
PMID: 38407228
ISSN: 1528-1140
CID: 5664592
Bipartite Diameter and Other Measures Under Translation
Aronov, Boris; Filtser, Omrit; Katz, Matthew J.; Sheikhan, Khadijeh
Let A and B be two sets of points in Rd, where | A| = | B| = n and the distance between them is defined by some bipartite measure dist(A,B). We study several problems in which the goal is to translate the set B, so that dist(A,B) is minimized. The main measures that we consider are (i) the diameter in two and higher dimensions, that is diam(A,B)=max{d(a,b)∣a∈A,b∈B}, where d(a, b) is the Euclidean distance between a and b, (ii) the uniformity in the plane, that is uni(A,B)=diam(A,B)-d(A,B), where d(A,B)=min{d(a,b)∣a∈A,b∈B}, and (iii) the union width in two and three dimensions, that is union_width(A,B)=width(A∪B). For each of these measures, we present efficient algorithms for finding a translation of B that minimizes the distance: For diameter we present near-linear-time algorithms in R2 and R3 and a subquadratic algorithm in Rd for any fixed d≥ 4 , for uniformity we describe a roughly O(n9 / 4) -time algorithm in the plane, and for union width we offer a near-linear-time algorithm in R2 and a quadratic-time one in R3.
SCOPUS:85137816295
ISSN: 0179-5376
CID: 5330602
Predicting Sepsis in Patients with Ureteral Stones in the Emergency Department
Margolin, Ezra Joseph; Wallace, Brendan K; Movassaghi, Miyad; Miles, Caleb; Shaish, Hiram; Golan, Ron; Katz, Matthew J; Anderson, Christopher B; Shah, Ojas
BACKGROUND:In the absence of overt infectious signs, clinical criteria for early intervention in patients with ureteral stones are poorly defined. We aimed to develop a model that can identify patients who are at risk for developing sepsis if discharged home from the emergency department (ED). MATERIALS AND METHODS/METHODS:We retrospectively reviewed patients between January 2010 and December 2019 who were discharged from the ED after diagnosis of ureteral stones. The primary outcome was sepsis requiring urgent surgical decompression. We used multivariable logistic regression to identify predictors of sepsis. We refined the model using backwards stepwise regression with a threshold p-value 0.05. RESULTS:We identified 1,331 patients who were discharged from the ED with ureteral stones. Of these patients, 22 (2%) subsequently developed sepsis requiring urgent decompression. In the initial multivariable model, female gender (OR 2.82, p=0.039) and urine white blood cells (WBC) (OR 1.02 per cell count, p<0.001) were predictive of sepsis. After performing backwards stepwise regression, female gender, urine WBC, and leukocytosis (WBC > 15,000/mm3) met criteria for inclusion in the model. A logistic model including these variables predicted sepsis with an internally cross-validated area under the curve of 0.79. Among patients with urine cultures completed in the ED, rates of sepsis were 9% in patients with positive cultures and 1% in patients with negative cultures (p<0.001). Antibiotic usage was not protective against developing sepsis. CONCLUSIONS:Sepsis is a rare complication among patients with ureteral stones selected for conservative management. The presence of elevated urine WBC and female gender can help identify patients who are at risk of developing sepsis. Patients with risk factors should be managed with an increased index of suspicion for infection and may benefit from early intervention to reduce the risk of sepsis. Sepsis is more common in patients with positive urine cultures.
PMID: 35156856
ISSN: 1557-900x
CID: 5175572
Intersection Queries for Flat Semi-Algebraic Objects in Three Dimensions and Related Problems
Chapter by: Agarwal, Pankaj K.; Aronov, Boris; Ezra, Esther; Katz, Matthew J.; Sharir, Micha
in: Leibniz International Proceedings in Informatics, LIPIcs by
[S.l.] : Schloss Dagstuhl- Leibniz-Zentrum fur Informatik GmbH, Dagstuhl Publishing, 2022
pp. ?-?
ISBN: 9783959772273
CID: 5316582
Dynamic Approximate Multiplicatively-Weighted Nearest Neighbors
Chapter by: Aronov, Boris; Katz, Matthew J.
in: Leibniz International Proceedings in Informatics, LIPIcs by
[S.l.] : Schloss Dagstuhl- Leibniz-Zentrum fur Informatik GmbH, Dagstuhl Publishing, 2022
pp. ?-?
ISBN: 9783959772365
CID: 5315922
FRONTIERS IN SURGERY [Review]
Lee, Justin; Katz, Matthew; Shah, Ojas
ISI:000726133700001
ISSN: 2296-875x
CID: 5993372
Developments in Ureteral Stent Technology
Lee, Justin; Katz, Matthew; Shah, Ojas
Ureteral stents have been utilized for decades in maintaining ureteral patency, most commonly after ureteroscopy in the treatment of urolithiasis. Since their initial development, ureteral stents have had many technological advances that have allowed for better patient outcomes with improvements in comfort, durability, patency, encrustation resistance, biocompatibility, ease of insertion, migration, and biofilm development. Several new ureteral stents enter the market every year, each with their own touted benefits. It is essential to understand the different advantages for each ureteral stent to provide the best available care to patients when possible. The purpose of this review is to give a brief history of ureteral stent development and summarize the recent developments in ureteral stent designs. We aim to review the data supporting the clinical advantages of the latest ureteral stents available for use by urologists.
PMCID:8637838
PMID: 34869565
ISSN: 2296-875x
CID: 5993002
Management of BPH and LUTS
Chapter by: Brucker, Benjamin; Katz, Matthew; Siev, Michael
in: Design and implementation of the modern men's health center : a multidisciplinary approach by Alukal, Joseph P; et al [Eds]
Cham, Switzerland : Springer, [2021]
pp. 127-152
ISBN: 9783030544812
CID: 5522452
Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes
Riquelme, Erick; Zhang, Yu; Zhang, Liangliang; Montiel, Maria; Zoltan, Michelle; Dong, Wenli; Quesada, Pompeyo; Sahin, Ismet; Chandra, Vidhi; San Lucas, Anthony; Scheet, Paul; Xu, Hanwen; Hanash, Samir M; Feng, Lei; Burks, Jared K; Do, Kim-Anh; Peterson, Christine B; Nejman, Deborah; Tzeng, Ching-Wei D; Kim, Michael P; Sears, Cynthia L; Ajami, Nadim; Petrosino, Joseph; Wood, Laura D; Maitra, Anirban; Straussman, Ravid; Katz, Matthew; White, James Robert; Jenq, Robert; Wargo, Jennifer; McAllister, Florencia
Most patients diagnosed with resected pancreatic adenocarcinoma (PDAC) survive less than 5 years, but a minor subset survives longer. Here, we dissect the role of the tumor microbiota and the immune system in influencing long-term survival. Using 16S rRNA gene sequencing, we analyzed the tumor microbiome composition in PDAC patients with short-term survival (STS) and long-term survival (LTS). We found higher alpha-diversity in the tumor microbiome of LTS patients and identified an intra-tumoral microbiome signature (Pseudoxanthomonas-Streptomyces-Saccharopolyspora-Bacillus clausii) highly predictive of long-term survivorship in both discovery and validation cohorts. Through human-into-mice fecal microbiota transplantation (FMT) experiments from STS, LTS, or control donors, we were able to differentially modulate the tumor microbiome and affect tumor growth as well as tumor immune infiltration. Our study demonstrates that PDAC microbiome composition, which cross-talks to the gut microbiome, influences the host immune response and natural history of the disease.
PMID: 31398337
ISSN: 1097-4172
CID: 5892992
Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer
Bernard, Vincent; Kim, Dong U; San Lucas, F Anthony; Castillo, Jonathan; Allenson, Kelvin; Mulu, Feven C; Stephens, Bret M; Huang, Jonathan; Semaan, Alexander; Guerrero, Paola A; Kamyabi, Nabiollah; Zhao, Jun; Hurd, Mark W; Koay, Eugene J; Taniguchi, Cullen M; Herman, Joseph M; Javle, Milind; Wolff, Robert; Katz, Matthew; Varadhachary, Gauri; Maitra, Anirban; Alvarez, Hector A
BACKGROUND & AIMS:We aimed to investigate the clinical utility of circulating tumor cell DNA (ctDNA) and exosome DNA (exoDNA) in pancreatic cancer. METHODS:We collected liquid biopsy samples from 194 patients undergoing treatment for localized or metastatic pancreatic adenocarcinoma from April 7, 2015, through October 13, 2017 (425 blood samples collected before [baseline] and during therapy). Additional liquid biopsy samples were collected from 37 disease control individuals. Droplet digital polymerase chain reaction was used to determine KRAS mutant allele fraction (MAF) from ctDNA and exoDNA purified from plasma. For the longitudinal analysis, we analyzed exoDNA and ctDNA in 123 serial blood samples from 34 patients. We performed analysis including Cox regression, Fisher exact test, and Bayesian inference to associate KRAS MAFs in exoDNA and ctDNA with prognostic and predictive outcomes. RESULTS:In the 34 patients with potentially resectable tumors, an increase in exoDNA level after neoadjuvant therapy was significantly associated with disease progression (P = .003), whereas ctDNA did not show correlations with outcomes. Concordance rates of KRAS mutations present in surgically resected tissue and detected in liquid biopsy samples were greater than 95%. On univariate analysis, patients with metastases and detectable ctDNA at baseline status had significantly shorter times of progression-free survival (PFS) (hazard ratio [HR] for death, 1.8; 95% CI, 1.1-3.0; P = .019), and overall survival (OS) (HR, 2.8; 95% CI, 1.4-5.7; P = .0045) compared with patients without detectable ctDNA. On multivariate analysis, MAFs ≥5% in exoDNA were a significant predictor of PFS (HR, 2.28; 95% CI, 1.18-4.40; P = .014) and OS (HR, 3.46; 95% CI, 1.40-8.50; P = .007). A multianalyte approach showed detection of both ctDNA and exoDNA MAFs ≥5% at baseline status to be a significant predictor of OS (HR, 7.73, 95% CI, 2.61-22.91, P = .00002) on multivariate analysis. In the longitudinal analysis, an MAF peak above 1% in exoDNA was significantly associated with radiologic progression (P = .0003). CONCLUSIONS:In a prospective cohort of pancreatic cancer patients, we show how longitudinal monitoring using liquid biopsy samples through exoDNA and ctDNA provides both predictive and prognostic information relevant to therapeutic stratification.
PMID: 30240661
ISSN: 1528-0012
CID: 5894632